(VIANEWS) – MERCK AND CO INC (MRK.PA) is among this list of stock assets with the highest dividend rate and return on equity on the Healthcare sector.
| Financial Asset | Price | Forward Dividend Yield | Return on Equity |
|---|---|---|---|
| MERCK AND CO INC (MRK.PA) | €101.40 | 2.61% | 29.69% |
| SARTORIUS STED BIO (DIM.PA) | €234.00 | 0.52% | 32.37% |
Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.
1. MERCK AND CO INC (MRK.PA)
2.61% Forward Dividend Yield and 29.69% Return On Equity
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. It has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics LP; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Earnings Per Share
As for profitability, MERCK AND CO INC has a trailing twelve months EPS of €4.82.
PE Ratio
MERCK AND CO INC has a trailing twelve months price to earnings ratio of 21.04. Meaning, the purchaser of the share is investing €21.04 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.69%.
Dividend Yield
As stated by Morningstar, Inc., the next dividend payment is on Jun 14, 2023, the estimated forward annual dividend rate is 2.7 and the estimated forward annual dividend yield is 2.61%.
Moving Average
MERCK AND CO INC’s worth is under its 50-day moving average of €103.30 and above its 200-day moving average of €99.53.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MERCK AND CO INC’s EBITDA is 4.88.
Revenue Growth
Year-on-year quarterly revenue growth declined by 8.9%, now sitting on 57.87B for the twelve trailing months.
More news about MERCK AND CO INC.
2. SARTORIUS STED BIO (DIM.PA)
0.52% Forward Dividend Yield and 32.37% Return On Equity
Sartorius Stedim Biotech S.A. produces and sells instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; batch and intensified chromatography systems for smaller molecules applications, such as oligonucleotides, peptides, and insulin; and recombinant albumin based solutions. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production. It serves manufacturers of medications, foods, and chemicals, as well as research and development laboratories. The company was founded in 1870 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Earnings Per Share
As for profitability, SARTORIUS STED BIO has a trailing twelve months EPS of €6.8.
PE Ratio
SARTORIUS STED BIO has a trailing twelve months price to earnings ratio of 34.41. Meaning, the purchaser of the share is investing €34.41 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.37%.
Growth Estimates Quarters
The company’s growth estimates for the present quarter and the next is 26% and 52.8%, respectively.
Earnings Before Interest, Taxes, Depreciation, and Amortization
SARTORIUS STED BIO’s EBITDA is 7.95.
Volatility
SARTORIUS STED BIO’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.66%, a negative 0.18%, and a positive 1.96%.
SARTORIUS STED BIO’s highest amplitude of average volatility was 4.25% (last week), 1.93% (last month), and 1.96% (last quarter).
Sales Growth
SARTORIUS STED BIO’s sales growth is negative 10.1% for the ongoing quarter and 2.2% for the next.
More news about SARTORIUS STED BIO.
